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Objective. To determine the proportion of initial troponin (cTn) elevations associated with Type I MI versus other cardiovascular
and noncardiovascular diagnoses in an emergency department (ED) and whether or not a relationship exists between the cTn level
and the likelihood of Type IMI.Background. In the ED, cTn is used as a screening test formyocardial injury.However, the differential
diagnosis for an initial positive cTn result is not clear. Methods. Hospital medical records were retrospectively reviewed for visits
associated with an initial positive troponin I-ultra (cTnI), ≥0.05 𝜇g/L. Elevated cTnI levels were stratified into low (0.05–0.09),
medium (0.1–0.99), or high (≥1.0). Discharge diagnoses were classified into 3 diagnostic groups (Type IMI, other cardiovascular, or
noncardiovascular). Results. Of 23,731 ED visits, 4,928 (21%) had cTnI testing. Of those tested, 16.3% had initial cTnI ≥0.05. Among
those with elevated cTn, 11%were classified as Type IMI, 34%had other cardiovascular diagnoses, and 55%had a noncardiovascular
diagnosis. Type IMI wasmore commonwith high cTnI levels (41% incidence) than among subjects withmedium (9%) or low (6%).
Conclusion. A positive cTn is most likely a noncardiovascular diagnosis, but Type I MI is far more common with cTnI levels ≥1.0.
1. Introduction
Myocardial infarction (MI) in emergency department (ED)
patients is a frequently suspected but infrequently made
diagnosis. In the ED patient population a troponin serum
assay (cTn) is used as a generic screen for myocardial injury
[1, 2]. Serum cTn testing is the biomarker of choice to test
for myocardial infarction, one of the more critical conditions
causing myocardial injury. An elevated troponin has been
associated with increased morbidity and mortality. So this
generally prompts a continued evaluation in hospital [3].The
biochemical specificity of contemporary cardiac troponin
assays, a troponin I (cTnI) upon initial serum testing in
the ED, is greater than 90% for myocardial injury [4, 5].
This permits the early identification of patients with likely
myocardial injury. A 2008 study by Keller et al. suggests that
the diagnosis of acute myocardial infarction can be made
early for many patients with an initial early elevated cTn level
in the right clinical context. However, the likelihood that an
initial elevated cTnI specifically represents Type I MI is less
clear. Troponin based diagnostic decision-making primarily
pertains to patients with potential non-ST-elevation MI
(NSTEMI), since the diagnosis of STEMI is made by EKG.
However, troponin testing still has a role in differentiating
cases of MI from those where ST elevations on EKG may be
attributed to other causes.
Even among causes of MI, there are several other mecha-
nisms of injury to be noted. In these cases, acutemanagement
focuses on treating the underlying causes, rather than med-
ication or procedural coronary intervention. This diversity
was recognized within the universal definition of myocardial
infarction as classified by the international consortium of
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Table 1: Types of myocardial infarction (MI).
Type Definition
I
Infarction due to ischemia from a primary coronary
event such as atherosclerotic plaque rupture and
thrombus formation, arterial wall erosion, fissuring,
or dissection
II
Infarction secondary to ischemia from either
increased oxygen demand or decreased supply
(coronary artery spasm, hypotension, hypertension,
anemia, and dysrhythmia)
III
Sudden cardiac death/arrest with symptoms
suggestive of STEMI or thrombus in a coronary
artery found on angiography or autopsy
IVa Infarction resulting from percutaneous coronaryintervention (PCI)
IVb Infarction from stent thrombosis
V Infarction due to ischemia related to coronary arterybypass grafting
cardiology associations. (see Table 1) [6]. Type I MI was
independently distinguished fromothermechanisms of acute
myocardial infarction (AMI), as myocardial cell loss from
ischemia caused by acute atherosclerotic plaque rupture
with thrombus formation within a coronary artery lumen,
fissuring, or dissection (i.e., acute coronary syndrome).
The loss of myocardium occurs on the order of minutes;
thus a diagnosis of Type I MI prompts an acute shift in
focus toward early antiplatelet and anticoagulant therapywith
the possibility of urgent percutaneous coronary intervention
(PCI). Little epidemiological data exists to guide practitioners
in gauging the suspicion for Type IMI, amongst other causes,
when the cTn is elevated in the context of a broad differential
diagnosis. This situation is typical in the ED. The first objec-
tive of this study is to assess the frequency and implications of
the diagnosis of Type I MI in an undifferentiated ED patient
population. In addition, it is commonly assumed that the
higher the cTn elevation, the greater the likelihood of Type
I MI. A 2001 substudy by Lindahl et al. [7] suggested that this
was the case with a cTnT assay. We challenge this hypothesis
using a cTnI assay.
2. Materials and Methods
2.1. Study Population. This study was performed at a tertiary
care academic medical and trauma center with 56,000 adult
ED patient visits a year using a sensitive contemporary
troponin biomarker for the evaluation of MI. Prior to the
initiation of this retrospective chart review, it was approved
by the hospital human research committee. The study period
was March 1–July 31, 2007. The study population included all
patients ≥18 years of age with a positive (≥0.05𝜇g/L) initial
ultrasensitive cTnI (TnI-Ultra, Siemens Healthcare Diagnos-
tics, Tarrytown, New York) [8, 9] during their ED evaluation.
Patients presenting in cardiac arrest were excluded. Typical
practice in the ED at this time was to test appropriate
patients for a cTn elevation upon initial evaluation and then
6 hours after presentation. Patients with a cTn elevation at
first measurement were included. Results were obtained from
the laboratory information system and merged, with the
associated patient data from the electronic medical record
system, in Microsoft Excel.
2.2. Adjudication of the Final Diagnosis. The final hospital
discharge diagnosis was confirmed through a review of each
patient’s ED and in-hospital record by a senior emergency
medicine attending physician. Patients were categorized into
diagnostic groups as either Type I MI (on the basis of care
consistent with MI management including urgent revascu-
larization, sustained antithrombotic therapy, or percutaneous
coronary intervention during the hospital course), other car-
diovascular diagnoses (including dysrhythmias, pulmonary
embolism, and congestive heart failure), or a noncardiovascu-
lar diagnosis. In addition, deaths and the incidence of urgent
revascularization were noted.
2.3. Analysis of Troponin Results. TnI results were strati-
fied as low (0.05–0.09𝜇g/L), medium (0.1–0.99 𝜇g/L), and
high (≥1.0 𝜇g/L). Frequencies of primary diagnoses were
determined by troponin strata, major diagnostic group-
ing, and the total population outcomes. The association of
diagnostic grouping and categorized cTn level was assessed
using Pearson’s chi-square test. All statistical analyses were
performed using the programming language R, Version 3.1.2
(http://cran.r-project.org/).
3. Results
During the 5-month study period, 23,731 patients were seen
in the ED of which 4,928 (21%) had a cTnI testing as part of
their ED evaluation (see Figure 1). Among the tested subjects,
804 had an elevated initial cTnI. This represents 3.4% of all
patients seen and 16.3% of those that had a cTnI ordered.The
leading causes of an elevated cTnI across all diagnostic groups
were from congestive heart failure (17%), infection (16%),
dysrhythmia (6%), and blood loss (4%). In the low troponin
level strata (0.05–0.9 ng/mL) were 383 patients (48%), 339
(42%) fell into the medium strata (0.1–0.99 ng/mL), and
82 (10%) fell into the high strata (≥1.0) (See Table 2). The
type of primary diagnosis was significantly associated with
categorized cTnI (𝑃 < 0.001). Eleven percent had a final
diagnosis of Type I MI. This was only 1.8% of those who had
a troponin level checked and 0.03% of all patients evaluated.
Fifteen (17%) had ST-elevationMI and 74 (83%) had non-ST-
elevation MI. Eight percent had urgent revascularization.
Among those with Type I MI, 26% had low troponin
levels, 36% hadmedium, and 38% had high. Sixty-six patients
(74%) underwent urgent revascularization, and 6% died.
These deaths accounted for a minority (7%) of all deaths.
Other cardiovascular diagnoses occurred in 277 (35%) of
patients with an elevated cTnI. The most frequent diagnoses
in this group were congestive heart failure (53%), dysrhyth-
mia (18%), and hypertension (9%). Ten (4%) of these patients
died accounting for 12% of all deaths. Noncardiovascular
diagnoses were identified for 438 (55%) patients. The top
diagnoses in this groupwere infection (29%), blood loss (7%),
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Figure 1: Study population and diagnostic groups.
Table 2: Positive troponin population data analysis by troponin level strata.
𝑁
Low Medium High Combined
𝑃 value
𝑁 = 383 𝑁 = 339 𝑁 = 82 𝑁 = 804
Age 804 59 72 82 58 70 81 57 67 80 58 71 81 0.221
Sex 804 0.952
Female 46% (177) 47% (160) 48% (39) 47% (376)
Male 54% (206) 53% (179) 52% (43) 53% (428)
First cTnI 804 0.05 0.06 0.08 0.12 0.20 0.35 1.73 3.00 6.29 0.06 0.10 0.27 <0.0011
Type of diagnosis 804 <0.0012
Type 1 MI 6% (23) 9% (32) 41% (34) 11% (89)
Other cardiovascular diagnoses 39% (148) 33% (111) 22% (18) 34% (277)
Noncardiovascular 55% (212) 58% (196) 37% (30) 54% (438)
eGFR 758 30 53 75 26 49 72 38 64 85 29 52 75 0.0151
CKMB 759 1.2 2.4 4.0 1.6 3.0 5.3 5.1 9.2 21.3 1.6 2.9 5.5 <0.0011
Creatinine 758 0.90 1.21 2.00 0.94 1.30 2.30 0.87 1.08 1.60 0.90 1.24 2.04 0.0261
MI 804 <0.0012
No 94% (360) 91% (307) 59% (48) 89% (715)
Yes 6% (23) 9% (32) 41% (34) 11% (89)
Urgent revascularization 804 <0.0012
No 95% (364) 94% (320) 66% (54) 92% (738)
Yes 5% (19) 6% (19) 34% (28) 8% (66)
Status 804 0.0012
Alive 93% (355) 88% (299) 79% (65) 89% (719)
Died 7% (28) 12% (40) 21% (17) 11% (85)
𝑎 𝑏 𝑐 represent the lower quartile 𝑎, the median 𝑏, and the upper quartile for continuous variables.
𝑁 is the number of nonmissing values.
Numbers after percents are frequencies.
Tests used: 1Kruskal-Wallis test; 2Pearson’s test.
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Table 3: Positive troponin population data analysis by diagnostic groups.
𝑁
Type I MI Other cardiovascular diagnoses Noncardiovascular Combined
𝑃 value
𝑁 = 89 𝑁 = 277 𝑁 = 438 𝑁 = 804
Age 804 57 64 77 57 69 80 60 74 83 58 71 81 <0.0011
Sex 804 0.382
Female 40% (36) 46% (128) 48% (212) 47% (376)
Male 60% (53) 54% (149) 52% (226) 53% (428)
First cTnI 804 0.09 0.34 2.49 0.06 0.09 0.21 0.06 0.10 0.24 0.06 0.10 0.27 <0.0011
First cTnI (categorized) 804 <0.0012
Low 26% (23) 53% (148) 48% (212) 48% (383)
Medium 36% (32) 40% (111) 45% (196) 42% (339)
High 38% (34) 6% (18) 7% (30) 10% (82)
eGFR 758 52 73 90 30 51 72 25 50 72 29 52 7 <0.0011
CKMB 759 1.9 3.6 9.5 1.6 2.7 4.2 1.5 2.9 5.6 1.6 2.9 5.5 0.0031
Creatinine 758 0.80 1.00 1.26 0.90 1.30 2.00 0.98 1.30 2.35 0.90 1.24 2.04 <0.0011
MI 804 <0.0012
No 0% (0) 100% (277) 100% (438) 89% (715)
Yes 100% (89) 0% (0) 0% (0) 11% (89)
Urgent revascularization 804 <0.0012
No 26% (23) 100% (277) 100% (438) 92% (738)
Yes 74% (66) 0% (0) 0% (0) 8% (66)
Status 804 <0.0012
Alive 94% (84) 96% (267) 84% (368) 89% (719)
Died 6% (5) 4% (10) 16% (70) 11% (85)
𝑎 𝑏 𝑐 represent the lower quartile 𝑎, the median 𝑏, and the upper quartile for continuous variables.
𝑁 is the number of nonmissing values.
Numbers after percents are frequencies.
Tests used: 1Kruskal-Wallis test; 2Pearson’s test.
and intracranial hemorrhage or stroke (7%). Seventy (16%) of
these patients died and accounted for 82% of all deaths.
In examining the troponin level (see Table 3) we found
that within the low strata 6% had a final diagnosis of
Type I MI, 5% underwent urgent revascularization, 39%
had other cardiovascular diagnoses, 55% of patients had a
noncardiovascular diagnosis (see Figure 2), and 7% died.
These deaths were 33% of all deaths. Within the medium
strata, 9% had an end diagnosis of Type I MI, 6% of
the group experienced urgent revascularization, 33% had
other cardiovascular diagnoses, 58%had a noncardiovascular
diagnosis, and 12% died. These deaths accounted for 47%
of all deaths. The leading diagnoses within this group were
dysrhythmiawith atrial fibrillation accounting for all cases. In
the high strata the leading diagnoses were Type I MI, AICD
firing, and blood loss. Within this group 41% of patients
had Type I MI, 34% had urgent revascularization, 22% had
other cardiovascular diagnoses, 37% had a noncardiovascular
diagnosis, and 21% of all patients with a high troponin died.
This was 20% of all deaths.
4. Discussion
This study demonstrates that myocardial infarction is the
cause of troponin elevation in a minority of cases. The
striking finding from the study is the diversity (see Figure 1)
within the differential diagnosis for an elevated cTnI in an
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undifferentiated patient population. The majority of deaths
among those with a positive troponin (82%) were attributed
Disease Markers 5
to noncardiovascular diagnoses. Our results support prior
work that has identified the incidence ofMI in this population
to be between 9 and 13% and the troponin elevations to be
mostly attributed to noncardiac diagnoses [10, 11]. However,
we also found that patients with high initial troponin levels
had a much higher incidence of Type I MI (see Figure 2).
The result of the first troponin test in the ED helps gauge the
likelihood of admission versus discharge and the likely focus
of early in-hospital care. Unlike other MI types, treatment is
focused on early antithrombotic coronary artery therapies.
Thus the likelihood of a positive initial troponin being Type
I MI is of high importance in priming these time-sensitive
interventions.
The specificity of a cTn elevation being attributed to
Type I MI increases with serial testing. Because of this,
the 2014 American College of Cardiology/American Heart
Association guidelines for the diagnosis and management
of NSTEMI advise measuring troponin levels at 3–6 hours
after symptoms onset and beyond 6 hours for patients with
amoderate to high risk [12]. However, an ideal ED evaluation
is completed at 4–6 hours, and the report of symptom onset
is not always reliable upon early patient evaluation in the
ED. This prompts many physicians to use ED arrival as their
start time for serial testing. As a result, decisions on whether
to admit or discharge patients, particularly when the initial
troponin is positive, are often made before serial testing is
completed.
In addition, many ED patients are undifferentiated, thus
undergoing simultaneous evaluations for other cardiovascu-
lar and noncardiovascular conditions that extend into their
in-hospital stay. A troponin elevation is only a marker of
myocardial injury, which can result from multiple mech-
anisms that cause myocyte death [13] including ischemia
from acute coronary syndrome (which includes STEMI
and NSTEMI), surgical trauma [14], mechanical trauma
[15], poorly understood neurohormonal and inflammatory
processes, and systemic demand [16]. Insight into the likely
differential diagnosis of an elevated troponin can help receiv-
ing in-hospital teams identify and target the true cause of
myocardia injury with more clarity.
The findings of this study shed light on the likely dif-
ferential diagnosis when myocardial injury is demonstrated
by an increased troponin level. Specifically, we found that
just under half of all positive tests were attributed to CHF,
infection, dysrhythmia, or blood loss.The quest for increased
sensitivity in identifying potential MI in patients has led to
biomarkers that have dramatically increased the number of
patients with a positive test. This study was performed at
time when this institution was switching from a cTnI assay to
the more sensitive cTnT. Both the department of pathology
and emergency medicine wanted to better understand the
end diagnostic nature of false positive tests when a troponin
was used to screen for myocardial infarction as a subset of
myocardial injury and to better understand the alternative
diagnoses to consider with a positive test.
Regardless of the etiology, an elevated cTnI result often
prompts a hospital admission for further investigation [17].
Serial troponin testing is more sensitive for the ultimate
diagnosis of Type I MI [18]. However, two 2009 studies by
Gudmundsson et al. [3] and Amsterdam et al. [12] note
the diagnostic sensitivity of an initial ultrasensitive or high-
sensitive ED cTnI assay in the early diagnosis of Type I MI.
Biochemical evidence of myocardial injury in the context of
concerns for MI will prompt an in-hospital stay, because this
finding increases the risk of a negative outcome regardless
of the etiology [3]. In our study we observed that mortality
trended with the level of troponin elevation.
5. Study Limitations
Some limitations of our study should be considered. This
is a retrospective study including data collected from a
heterogeneous mix of patients. Each patient had a cTnI
blood level sent by a heterogeneous group of emergency
medicine physicians that were not using a standard protocol
to screen for myocardial injury or infarction. There is no
strict policy or protocol for when to test for a troponin I
level in this institution. However, all troponins require a
physician order to be processed. We did not follow the final
diagnosis of patients whose cTnIs were negative during their
ED stay or any associated hospital stay. This prevented us
from identifying the negative and positive predictive values
of the initial ED troponin in the population of patients being
evaluated for Type IMI andwe did not assess the implications
of serial troponin testing as this was outside the scope of
this study. Many “other cardiovascular” diagnoses qualify as
MI. However, they are typically Type II MI which is from
increased oxygen demand or decreased oxygen supply to the
demand or restrictions of another cardiovascular pathology.
However, given our intent to identify those patient who will
receive early acute coronary syndrome intervention this study
is limited to the identification of individuals with Type I MI.
6. Conclusion
Concerns for potential MI may be the primary reason for
testing, but a minority of patents with a positive result had
Type I MI as their final diagnosis. Most common diagnoses
were congestive heart failure, infections, dysrhythmias, and
blood loss. In addition, the majority of deaths were due to
alternative diagnoses with most falling in the noncardiovas-
cular diagnostic group. This supports existing evidence that
myocardial injury is a marker of increased morbidity and
mortality. We also observed an increasing trend in mortality
correlating to the level of troponin elevation. In comparing
troponin strata, Type IMI was more common in the medium
strata than the low strata and significantly more present
in the high troponin strata. Overall, a patient who has a
positive cTnI will most likely have other cardiovascular or
noncardiovascular diagnoses since only 11% of all patients
had Type I MI.
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